Clinical trial Recruiting at 2 sites Interventional Ages 18 to 35

Regenerative Gel to Support Second Molar Health After Wisdom Tooth Extraction

Official title: The Role of Enamel Matrix Derivative in Reducing the Periodontal Defect Distal to the Mandibular Second Molar Following Surgical Extraction of the Third Molar

Run by Aristotle University Of Thessaloniki · NCT07718932 · Data updated 2026-11-12

A 70-patient study is testing whether applying Enamel Matrix Derivative (Emdogain) during the removal of an impacted lower wisdom tooth helps protect the neighboring second molar from tissue defects.

Quick facts

Study typeInterventional
Ages18 Years to 35 Years
SexAll
Enrollment70 (estimated)
SponsorAristotle University Of Thessaloniki
Academic / other
Locations2 sites (Thessaloniki and 1 other locations)
StatusRecruiting
StartedMarch 9, 2026
Main results expectedSeptember 30, 2027
Study endsOctober 30, 2027
Registry record updatedJuly 22, 2026
Trial IDNCT07718932 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Healthy adults ages 18–35 (or 18–45 per protocol) with an impacted lower third molar causing proximity to the second molar and good oral hygiene.

Probably not a fit

Patients whose second molars do not develop defects or those not receiving the targeted defect prevention may not experience additional benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a two-center randomized trial evaluating whether placing Emdogain at the time of wisdom tooth extraction improves long-term periodontal health of the adjacent second molar. Eligible participants are healthy adults aged 18–45 with a horizontally or mesially impacted lower third molar that touches the second molar. The study uses standardized clinical measurements at multiple sites around the second molar to assess tissue outcomes and compares EMD treatment to standard care. Primary goal is to see if the site-specific intraoperative application reduces distal tissue defects after extraction. The trial aims to generate reproducible data through strict inclusion criteria and measurement protocols.

Why it matters

Potential benefit: If successful, patients could have better protection of the second molar after wisdom tooth extraction, potentially reducing future gum or bone defects.

How similar studies have gone: EMD has shown regenerative benefits in periodontal contexts, but its prophylactic, site-specific use at extraction is a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Healthy adult patients aged 18 to 35 years old (ASA I or II).
* Presence of an asymptomatic, partially or fully impacted mandibular third molar requiring surgical extraction.
* The third molar impaction must be mesioangular or horizontal, with its crown in direct physical contact with the adjacent second molar, as assessed by a preoperative panoramic radiograph.
* The adjacent mandibular second molar must be vital, fully erupted, and structurally sound (free of extensive dental caries or prosthetic crowns).
* Patients must demonstrate an adequate level of overall oral hygiene and gingival health (e.g., Full-Mouth Plaque Index \< 20% and Full-Mouth Bleeding Score \< 20% following initial prophylaxis and oral hygiene instructions).
* Willingness to comply with postoperative instructions and adhere to the scheduled follow-up visits.
* Ability to understand the study procedures and voluntarily sign the informed consent form.

Exclusion Criteria

* Presence of systemic diseases or conditions that could compromise wound healing or periodontal health (e.g., uncontrolled diabetes mellitus, autoimmune disorders).
* Current or recent use of medications known to affect bone metabolism or wound healing (e.g., bisphosphonates, long-term systemic corticosteroids, immunosuppressants).
* History of heavy smoking (e.g., \>10 cigarettes per day) or use of smokeless tobacco products.
* Pregnant or lactating females.
* Diagnosis of periodontitis (Stage II, III, or IV) affecting the remaining dentition, excluding the localized defect associated with the impacted third molar.
* Presence of active acute infection (e.g., purulent pericoronitis) or radiolucent pathologic lesions extending beyond the normal follicular space (e.g., dentigerous cysts) that would significantly alter the baseline bony defect morphology.
* Known allergy or hypersensitivity to any of the medications utilized in the surgical or postoperative protocol (e.g., local anesthetics, prescribed antibiotics, or analgesics).
* Previous orthodontic treatment utilizing bands on the mandibular second molars that could have affected the periodontal attachment.

Where it's running

  • 424 General Military Hospital
    Thessaloniki, Greece
    Recruiting
  • Aristotle University of Thessaloniki
    Thessaloniki, Greece
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.